Reports & eBooks

Drug Pipeline & Clinical Update - January 2024

February 14, 2024

Capital Rx


  • One new approval - Zelsuvmi™ topical gel
  • Three new notable expanded indications
  • One biosimilar approval: Udenyca Onbody
  • One notable generic launch - Prolensa®
  • Capital Rx's Updated Drug Recall Report: CLICK HERE to review

Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our January 2024 Monthly Drug Update!

Key New Drug Approvals

Zelsuvmi™  (berdazimer) topical gel

Approval Date: 01/05/2024 - CLICK HERE for the press release

Indication: Molluscum contagiosum

Cost*: TBD

Key Considerations:

Notable Expanded Indications

Keytruda® (pembrolizumab) intravenous solution- expanded to be used in combination with chemotherapy with or without bevacizumab for the treatment of adults with persistent, recurrent, or metastatic cervical cancer

HyQvia® (immune globulin infusion/recombinant human hyaluronidase) subcutaneous injection- expanded to be used for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults

Balversa® (erdafitinib) tablet- expanded to be used for the treatment of adult patients with locally or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy

Biosimilar Approvals

Udenyca Onbody™  (pegfilgrastim-cbqv) subcutaneous injection

Approval Date: 12/26/2023 - CLICK HERE for the press release

Indication: Administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia

Additional Information:

Generic Launches

Prolensa® (bromfenac 0.07%) ophthalmic solution

Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.


* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

DOWNLOAD NOWBack to Insights

Sign up for our newsletter!

Get the latest information on JUDI news, webinars, and industry insights through our newsletter. Sign up now!